AnaCardio
PrivateLast Round
Series B
Sep 30, 2026
Est. Valuation
$1.71M
Total Funding Raised
$104.16M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
AnaCardio is a clinical-stage biopharmaceutical company that develops novel drugs to treat heart failure.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AnaCardio Comparables
Compare AnaCardio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cardurion Pharmaceuticals | 85% | |
| Thryv Therapeutics | 82% | |
| Windtree Therapeutics, Inc. | 77% |
AnaCardio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 30, 2026 | ||||
| Series A Extension | Jan 9, 2025 | ||||
| Series A | Sep 7, 2022 | ||||
| VC Round | Feb 3, 2022 | ||||
| Seed | Jun 17, 2021 |
Key People
Founding team and executive leadership
AnaCardio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovestor | Series B |
| Innovestor Life Science | Series B |
| 3B FUTURE Health Fund | Series B, Series A |
| Industrifonden | Series A Extension, Series B, VC Round, Series A |
| Novo Holdings | Series A Extension, Series B |
| Karolinska Development AB | Series A, VC Round, Seed |
| Pureos Bioventures | Series B, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 30, 2026
$71M round led by Novo Holdings
- Sep 12, 2026
Monthly visitors increased 241% MoM.
Recent news
Latest coverage and updates
- receives_financingOct 3, 2026
AnaCardio AB announced $19M Series A financing in Jan '25
- receives_financingSep 30, 2026
AnaCardio AB receives financing of $62.5M in Series A Plus.
- receives_financingSep 30, 2026
AnaCardio AB completed a $71M Series B financing in Sweden on Sep 30th '26, co-led by Novo Holdings and the Ljungström family office to fund AC01 through Phase 2b development.
AnaCardio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about AnaCardio's valuation, stock price, and market status.
Is AnaCardio a public or private company?
AnaCardio is a private company.
What is the current stock price of AnaCardio?
AnaCardio is a private company, so its shares have no public market price. Caplight tracks AnaCardio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is AnaCardio worth (valuation)?
AnaCardio's valuation is estimated at $1.7M based on funding round data.
Can I buy AnaCardio stock?
AnaCardio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was AnaCardio's last funding round?
AnaCardio's most recent funding round was Series B on September 30, 2026.
Who are the main investors in AnaCardio?
Key investors in AnaCardio include Industrifonden, Novo Holdings, Karolinska Development AB, Pureos Bioventures, Flerie AB.
Will AnaCardio IPO soon?
No public IPO plans have been announced for AnaCardio.
How can I track AnaCardio secondary market activity?
Caplight tracks bids, offers, and trades in AnaCardio's shares on secondary markets.